Daniel Joseph OConnell - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Reporting relationship: President and CEO, Director
Issuer ticker: ABOS
Reported as of: 06 Jul 2021
Net transaction value: -$3.55
SEC form: 4
Accepted by SEC: 08 Jul 2021, 18:16:31 UTC
Prior SEC filing: 30 Jun 2021
Next SEC filing: 02 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ Katherine Denby, Attorney-in-Fact

Key filing fact

Daniel Joseph OConnell filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 08 Jul 2021.

Key facts

This page summarizes Daniel Joseph OConnell's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 08 Jul 2021, 18:16.

Change

Previous filing in this sequence was filed on 30 Jun 2021.
Current net transaction value: -$3.55.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABOS transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +123
Change %: +8.7%
Price
Shares after: 1,542
Date: 06 Jul 2021
Ownership: Direct
Footnotes: F1

ABOS transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value: $156
Shares: +35
Change %: +2.3%
Price: $4.47
Shares after: 1,577
Date: 06 Jul 2021
Ownership: Direct

ABOS transaction

Common Stock

Tax liability

Transaction value: $160
Shares: -10
Change %: -0.63%
Price: $16.00
Shares after: 1,567
Date: 06 Jul 2021
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABOS transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value
Shares: -123
Change %: -100%
Price
Shares after: 0
Date: 06 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 123
Exercise price
Footnotes: F1

ABOS transaction Derivative

Warrant (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -35
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 06 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35
Exercise price: $4.47

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On July 6, 2021, each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Footnote F2

On July 6, 2021, the reporting person exercised a warrant to purchase 35 shares of ABOS common stock for $4.47 a share. The reporting person paid the exercise price on a cashless basis, resulting in ABOS's withholding of 10 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 25 shares.